Shareholders in Talecris Biotherapeutics (Nasdaq: TLCR) will be asked to approve the life science company’s merger with Spain-based Grifols on Feb. 14.

The meeting had originally been scheduled for Jan. 21.

Last week, Grifols completed financing it needed for the takeover of Talecris, which has major operations in RTP and in Clayton.

Talecris shareholders as of Jan. 11 can vote.

The meeting will take place at the Research Triangle Park Marriott hotel at 3:30 p.m.
Grifols sold $1.1 billion in bonds last week, according to IFR, a Thomson Reuters service.

The sale of notes through a private placement was managed by Deutsche Bank, Nomura, BBVA Securities, BNP Paribas, HSBC and Morgan Stanley, IFR said.

Grifols had encountered delays in securing financing. According to Reuters, Grifols had hoped to sell the bonds in December. A banker told Reuters the problem was the debt crisis taking place in the European Union.

Grifols also has secured a $300 million revolving credit to help finance the takeover. The merger was announced last June.

The financing includes:

• $1.5 billion in commitments from financial institutions
• $1.6 billion from institutional investors
• $1.1 billion in bonds
• A $300 million revolving credit line

The deal also includes the assumption of some $600 million in Talecris debt.

Get the latest news alerts: Follow LTW at Twitter.